| dc.date.accessioned | 1399-07-08T18:15:35Z | fa_IR |
| dc.date.accessioned | 2020-09-29T18:15:35Z | |
| dc.date.available | 1399-07-08T18:15:35Z | fa_IR |
| dc.date.available | 2020-09-29T18:15:35Z | |
| dc.date.issued | 2014-12-01 | en_US |
| dc.date.issued | 1393-09-10 | fa_IR |
| dc.identifier.citation | (2014). Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles. Asian Pacific Journal of Cancer Prevention, 15(23), 10281-10287. | en_US |
| dc.identifier.issn | 1513-7368 | |
| dc.identifier.issn | 2476-762X | |
| dc.identifier.uri | http://journal.waocp.org/article_30260.html | |
| dc.identifier.uri | https://iranjournals.nlai.ir/handle/123456789/39891 | |
| dc.description.abstract | <b>Background:</b> Development of a nanosized polymeric delivery system for erlotinib was the main objectiveof this research. Materials and <br/><b>Methods</b>: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC)copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblockcopolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by meansof synthesized copolymers with solvent displacement method. <br/><b>Results</b>: Physicochemical properties of obtainedpolymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased withdecreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulationswas declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibiteda sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release ratefrom polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers.Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8μM. <br/><b>Conclusions</b>: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in thisstudy might have the potential to be considered as delivery system for erlotinib. | en_US |
| dc.format.extent | 892 | |
| dc.format.mimetype | application/pdf | |
| dc.language | English | |
| dc.language.iso | en_US | |
| dc.publisher | West Asia Organization for Cancer Prevention (WAOCP) | en_US |
| dc.relation.ispartof | Asian Pacific Journal of Cancer Prevention | en_US |
| dc.subject | erlotinib | en_US |
| dc.subject | PCEC | en_US |
| dc.subject | solvent displacement method | en_US |
| dc.subject | Nanoparticles | en_US |
| dc.title | Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles | en_US |
| dc.type | Text | en_US |
| dc.citation.volume | 15 | |
| dc.citation.issue | 23 | |
| dc.citation.spage | 10281 | |
| dc.citation.epage | 10287 | |